1. Adams R, Hunt M, Clark JH. Structure of Cannabidiol, a Pro duct Isolated from the Marihuana Extract of Minnesota Wild Hemp. J Am Chem Soc 1940; 62 (1): 196–200.
2.
AES Position Statement on Cannabis as a Treatment for Pa tients with Epileptic Seizure;
3.
https://www.aesnet.org/sites/default/files/file_attach/ 42981132_cannabis_position_statement_updated_2.19.19.pdf (data cytowania 27.04.2020).
4.
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Ma kriyannis A, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300–302.
5.
Bergamaschi M, Queiroz, RH, Zuardi WA, Crippa, JA. Safety and Side Effects of Cannabidiol, a Cannabis sativa Constitu ent. Current Drug Safety 2011; 6(4): 237–249.
6.
Bernal-Chico A, Canedo M, Manterola A, Sánchez-Gómez VM, Pérez-Samartín A, Rodríguez-Puertas R et al. Blockade of monoacylglycerol lipase inhibits oligodendrocyte exci totoxicity and prevents demyelination in vivo. Glia 2015; 63(1): 163–176.
7.
Bifulco M, Pisanti S. Medicinal use of cannabis in Europe, The fact that more countries legalize the medicinal use of cannabis should not become an argument for unfettered and uncontrolled use. EMBO reports 2015; 16: 130–132.
8.
Bogucki A, Sławek J, Boczarska-Jedynak M, Gajos A, Opa la G, Rudzińska M, et al. Leczenie zaawansowanej choroby Parkinsona – rekomendacje Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych. Pol Przegl Neurol 2014; 10(1): 15–22.
9.
Carroll CB, Bain PG, Teare L. Cannabis for dyskinesia in Par kinson disease: a randomized double-blind crossover study. Neurol 2004; 63: 1245–1250.
10.
Chagas MH, Zuardi AW, Tumas V, Pena-Pereira MA., Sobre ira ET, Bergamaschi MM et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an explo ratory double-blind trial. J Psychopharmacol 2014; 28(11): 1088–1092.
11.
Chiurchiùa V, Van der Steltc M, Centonzed D, Maccarrone M. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Progress in Neurobiol 2018; 160: 82–100.
12.
Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32(5): 451–459.
13.
Collingwood L, O’Brien BG, Dreier S. Evaluating ballot initia tive support for legalised marijuana: The case of Washington. Int J Drug Policy 2018; 56: 6–20.
14.
Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG. Is cannabidiol the ideal drug to treat non--motor Parkinson’s disease symptoms. Eur Arch Psychiatry Clin Neurosci 2019; 269(1): 121–133.
15.
Dąbrowska K, Miturska E, Moskalewicz J, Wieczorek Ł. Co mówią wyniki badań o szkodliwości zażywania marihuany? Przegląd badań. Serwis Info Narkomania 2012; 3(59): 33–38.
16.
Devinsky O, Cross JH, Laux L. Trial of cannabidiol for dru g-resistant seizures in the Dravet syndrome, N Engl J Med 2017; 376: 2011–2020.
17.
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sulli van J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016; 15(3): 270–278.
18.
Foldy C. Presynaptic, Activity-Dependent Modulation of Cannabinoid Type 1 Receptor-Mediated Inhibition of GABA Release. J Neurosci 2006; 26(5): 1465–1469.
19.
Frassinettia S, Mocciaa E, Caltavuturoa L, Gabrielea M, Longoa V, Bellania L i wsp. Nutraceutical potential of hemp (Cannabis sativa L.) seeds and sprouts. Food Chem 2018; 262: 56–66.
20.
Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Syn thesis of an Active Constituent of Hashish, J Am Chem Soc 1964; 86 (8): 1646–1647.
21.
Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interac tions between cannabidiol and commonly used antiepileptic drugs. Epilepsia 2017; 58(9): 1586–1592.
22.
Gaweł M, Potulska-Chromik A. Choroby neurodegeneracyj ne: choroba Alzheimera i Parkinsona. Post N Med 2015: 28(7): 468–476.
23.
Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecu lar cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279(1): 129–134.
24.
Giancaspro GI, Kim NC, Venema J, de Mars S, Devine J, Cele stino C, et al. The Advisability and Feasibility of Developing USP; https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/usp-nf-notices/usp_stim_article_medical_can nabis.pdf (data cytowania 25.04.2020).
25.
Gonzalez S, Scorticati C, Garcia-Arencibia M. Effects of rimonabant, a selective cannabinoid CB1 receptor antago nist, in a rat model of Parkinson’s disease. Brain Res 2006; 1073–1074: 209–219.
26.
García C, Palomo-Garo C, García-Arencibia M, Ramos J, Pertwee R, Fernández-Ruiz J. Symptom-relieving and neu roprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease. Br J Pharmacol 2011; 163(7): 1495–1506.
27.
Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374: 1383–1391.
28.
Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E., Lay J, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome. Epilep sy Behav 2015; 47: 138–141.
29.
Jędrzejczak J, Majkowska-Zwolińska B, Ryglewicz D, Na gańska E, Mazurkiewicz-Bełdzińska M, Zalecenia Polskiego Towarzystwa Epileptologii dotyczące leczenia napadów pa daczkowych u dorosłych. Aktualizacja. J Epileptology 2019; 27(1): 5–12.
30.
Kaczmarczyk-Sedlak I, Wojnar W, Zych M, Dudek S. Lecz nicze właściwości konopi i możliwości ich zastosowania w medycynie Katedra i Zakład Farmakognozji i Fitochemii, Wydział Farmaceutyczny z Oddziałem Medycyny Laborato ryjnej w Sosnowcu, Śląski Uniwersytet Medyczny w Kato wicach 2017; https://katowice.oia.pl/files_news/news_7341/files/Lecznicze_wlasciwosci_konopi_Kaczmarczyl_Sedlak_Ilona_SUM_2017.pdf (data cytowania 25.04.2020).
31.
Kilpeläinenb P, Kitunenb V, Lappalainena R, Tomppoa L, Väisänena T. Effect of steam treatment on the chemical com position of hemp (Cannabis sativa L.) and identification of the extracted carbohydrates and other compounds. Ind Crops Prod 2019; 131: 224–233.
32.
Koppel BS, Brust JCM . Fife T, Bronstein J, Youssof S, Gron seth G, et al. Systematic review: Efficacy and safety of me dical marijuana in selected neurologic disorders, Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurol 2014; 82(17): 1556–1563.
33.
Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease mo dels. Nature 2007; 445: 643–647.
34.
Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, et al. A double-blind, randomized, placebo-con trolled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013; 260(4): 984–997.
35.
Legalizacja marihuany w Urugwaju; https://www.canna bisnews.pl/legalizacja-marihuany-w-urugwaju/ (data cy towania 20.04.2020).
36.
Leizer C, Ribnicky D, Poulev A, Dushenkov S, Raskin I. The composition of hemp seed oil and its potential as an im portant source of nutrition. J Nutraceuticals, Functional & Medical Foods 2000; 2(4): 35–53.
37.
Marihuana rekreacyjna na świecie; https://www.cannabisnews.pl/marihuana-rekreacyjna-na-swiecie/ (data cytowa nia 20.04.2020).
38.
Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, et al. Sativex as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistantmultiple sclerosis spasticity: a double-blind, placebo-con trolled randomised clinical trial. Int J Neurosci 2019; 129(2): 119–128.
39.
Mathre ML. Cannabis in Medical Practice: A Legal, Histori cal and Pharmacological Overview of the Therapeutic Use of Marijuana, Wydawnictwo McFarland & Company 1997, Jefferson, 3: 35–49.
40.
Mauryaa N, Velmurugan BK. Therapeutic applications of cannabinoids, Chem-Biol Interact 2018; 293: 77–88.
41.
Mikuriya TH. Marijuana in medicine: past, present and fu ture. CalifMed. 1969; 110(1): 34–40.
42.
Motyka M, Marcinkowski JT. Używanie pochodnych konopi. Część II. Zastosowanie w medycynie vs. konsekwencje zdro wotne. Probl Hig Epidemiol 2014; 95(1): 21–27.
43.
Mounsey RB, Mustafa S, Robinson L, Ross RA, Riedel G, Pertwee RG, et al. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Exp Neurol 2015; 273: 36–44.
44.
Munro S, Thomas KL, Abu-Shaar M. Molecular characte rization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61–65.
45.
Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, et al. Cannabidiol exerts sebostatic and antiinflammato ry effects on human sebocytes. J Clin Invest 2014; 124(9): 3713–3724.
46.
Pertwee RG. Cannabinoid pharmacology: the first 66 years, Br J Pharmacol 2006; 147(1): 163–171.
47.
Perucca E. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last. J Epilepsy Res 2017; 7(2): 61–76.
48.
Porter BE, Jacobson C. Report of a parent survey of cannabi diol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013; 29(3): 574–577.
49.
Press CA, Knupp KG, Chapman KE. Parental reporting of re sponse to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav 2015; 45: 49–52.
50.
Przybek J, Członkowski A, Mirowska-Guzel D. Kannabino idy w leczeniu stwardnienia rozsianego. MS Report 2017; 6/1(20): 21–26.
51.
Rozenek H, Owczarek K. Warunki funkcjonowania chorych na padaczkę wpływające na jakość życia. Neurol Dypl 2010; 5(6): 37–43.
52.
Russo E. Cognoscenti of Cannabis I: Jacques-Joseph Moreau (1804-1884). Journal of Cannabis Therapeutics 2001; 1(1): 85–88.
53.
Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B. Can nabidiol targets mitochondria to regulate intracellular Ca2+levels. J Neurosci 2009; 29(7): 2053–2063.
54.
Scholten WK. The mechanism of action of cannabis and cannabinoids, Ned. Tijdschr. Geneeskd 2006; 150: 128–131.
55.
Sieradzan KA, Fox SH, Hill M. Cannabinoids reduce levod opa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurol 2001; 57: 2108–2111.
56.
Silska G. Konopie jako źródło kanabinoidów stosowanych w terapii. Post Fitoter 2017; 18(4): 286–289.
57.
Siudem P, Wawer I, Paradowska K. Konopie i kannabinoidy. Farmacja Współcz 2015; 8: 1–8.
58.
State Medical Marijuana Laws, National Conference of State Legislatures. June 27, 2018. Retrieved July 3, 2018.
59.
van der Stelt M, Fox SH, Hill M. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson’s disease. FASEB J 2005; 19: 1140–1142.
60.
Świątek M. Stwardnienie rozsiane – przyczyny, rodzaje, objawy i leczenie. GF 2016; 24–26.
61.
Tennstedt D, Saint-Remy A. Cannabis and skin diseases. Eur J Dermatol 2011; 21(1): 5–11.
62.
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome- a ran domised, double-blind, placebo-controlled phase 3 tria. Lancet 2018; 391(10125): 1085–1096.
63.
Touwn M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs 1981; 13(1): 23–34.
64.
Ustawa z dnia 29 lipca 2005 r. o przeciwdziałaniu narko manii; http://isap.sejm.gov.pl/isap.nsf/download.xsp/WDU20051791485/T/D20051485L.pdf (data cytowania 1.05.2020).
65.
Ustawa z dnia 7 lipca 2017 r. o zmianie ustawy o przeciwdzia łaniu narkomanii oraz ustawy o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych; http://isap.sejm.gov.pl/isap.nsf/download.xsp/WDU20170001458/T/D20171458L.pdf (data cytowania 2.05.2020).
66.
Vetulani J. Lecznicze zastosowania marihuany. Wszechświat 2014; 115 (1–3): 15–24.
67.
Vetulani J, Mazurek M. A w konopiach strach. Wydawnictwo PWN, Warszawa 2016.
68.
Wachowiak R, Krawczyński M, Steinborn B. Stan aktual ny i perspektywa stosowania kannabinoidów („medyczna marihuana”) w terapii dzieci. Przegląd opinii i stanowisk. Neurol Dziec 2016; 25(51): 55–65.
69.
Wade DT, Makela P, Robson P, House H, Bateman C. Do can nabis-based medicinal extracts have general or specific ef fects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patient. Mult Scler 2004; 10: 434–441.
70.
Wade DT, Makela P, House H, Bateman C, Robson P. Long term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12(5): 639–45.
71.
Wojnar M. Standardy postępowania wobec osób używają cych nowych substancji psychoaktywnych (NSP). Poradnik dla pracowników medycznych, Warszawa 2018, 69–72.
72.
Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006; 28 (2): 153–157.
